Abstract Relcobatinib (ELVN-001) is a next-generation, investigational, BCR::ABL1 active-site tyrosine kinase inhibitor (TKI) with a unique P-loop folded-in binding mode designed to deliver best-in-class efficacy with an improved tolerability profile over that of other TKIs for the treatment of chronic myeloid leukemia (CML).
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Christopher A. Eide
CDK4/6 inhibition overcomes venetoclax resistance mechanisms with enhanced combination activity in acute myeloid leukemia
Keywords targeted therapy cell state monocytic progenitor Introduction In recent years, initial remission rates for elderly patients with acute myeloid leukemia (AML) have seen improvement due to the combination therapy of the BCL2 inhibitor venetoclax (ven) with hypomethylating agents azacitidine (aza) and decitabine.1,2 However, drug resistance and disease relapse continue to be major hurdles in the long-term management and overall survival of patients with AML due to the heterogeneity of...
Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminib
Editor’s summary The oncogenic fusion proteins BCR-ABL and TEL-ABL drive hematologic malignancies through the constitutive activation of the tyrosine kinase ABL. Both fusion proteins are sensitive to ATP-competitive tyrosine kinase inhibitors, but Muratcioglu et al. found that only BCR-ABL was sensitive to the allosteric ABL inhibitor asciminib, which stabilizes ABL in an autoinhibited conformation.
Autophosphorylation of the oncogenic protein TEL-ABL confers resistance to the allosteric ABL inhibitor asciminib
Abstract Chromosomal translocations that fuse the ABL1 gene to BCR and TEL cause human leukemias. Oligomerization and the loss of an inhibitory myristoylation modification lead to unregulated kinase activity of the BCR-ABL and TEL-ABL fusion proteins. ATP-competitive ABL inhibitors, such as imatinib and ponatinib, are effective against both fusion proteins.
Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy
1Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA 2Department of Structural Biology, St. Jude Children’s Research Hospital, Memphis, TN, USA 3Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN, USA 4Department of Pathology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA 5Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, The...
Response and Resistance to BCR-ABL1-Targeted Therapies
Chronic myeloid leukemia (CML), caused by constitutively active BCR-ABL1 fusion tyrosine kinase, has served as a paradigm for successful application of molecularly targeted cancer therapy. The development of the tyrosine kinase inhibitor (TKI) imatinib allows patients with CML to experience near-normal life expectancy. Specific point mutations that decrease drug binding affinity can produce TKI resistance, and second- and third-generation TKIs largely mitigate this problem.
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants
Highlights • Most BCR-ABL1 point mutants but not compound mutants are sensitive to asciminib • Variants at BCR-ABL1 position F359 are linked with asciminib resistance in patients • Combination of asciminib with ponatinib restores efficacy against compound mutants Summary BCR-ABL1 point mutation-mediated resistance to tyrosine kinase inhibitor (TKI) therapy in Philadelphia chromosome-positive (Ph +) leukemia is effectively managed with several approved drugs, including ponatinib for BCR-ABL1...
Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation
Translational Science George M. Burslem, Anna Reister Schultz, Daniel P. Bondeson, Christopher A. Eide, Samantha L. Savage Stevens, Brian J. Druker and Craig M. Crews DOI: 10.1158/0008-5472.CAN-19-1236 Published September 2019 This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-mediated Targeted Protein Degradation
Research Article George M Burslem, Anna Reister Schultz, Daniel P Bondeson, Christopher A. Eide, Samantha L Savage Stevens, Brian J. Druker and Craig M Crews DOI: 10.1158/0008-5472.CAN-19-1236 Abstract While the use of ATP-competitive tyrosine kinase inhibitors of oncoprotein BCR-ABL1 has enabled durable responses in patients with chronic myeloid leukemia (CML), issues of drug resistance and residual leukemic stem cells remain.
Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia
JWT receives research support from Agios, Aptose, Array, AstraZeneca, Constellation, Genentech, Gilead, Incyte, Janssen, Seattle Genetics, Syros, Takeda; JWT is a co-founder of Leap Oncology. BJD serves on the advisory boards for Gilead, Aptose, and Blueprint Medicines. BJD is principal investigator or coinvestigator on Novartis and BMS clinical trials. His institution, OHSU, has contracts with these companies to pay for patient costs, nurse and data manager salaries, and institutional overhead.
Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia
In some acute myeloid and juvenile myelomonocytic leukemias (AML and JMML, respectively), tumor growth is driven by activating mutations in the phosphatase PTPN11. Jenkins et al. found that mutant PTPN11 activity is enhanced by the kinase TNK2.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Christopher A.
Contact Christopher A., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack